GlassScriptPhysician profile
Taylor Rouser
NPI 1861141442
$1,784.88
in general payments reported to CMS, 2019-2025
23 companies · $77.60 in 2025
The $77.60 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $382 · 2023: $1,063 · 2024: $262 · 2025: $77.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.73 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $220.71 | 2022-2025 | |
| Lilly USA, LLC | $199.03 | 2022-2024 | Mounjaro, Trulicity |
| Pfizer INC. | $162.80 | 2022-2024 | |
| Medtronic, INC. | $106.34 | 2023-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Glaxosmithkline, LLC. | $102.81 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $91.72 | 2022-2024 | Breztri, Fasenra, Airsupra |
| Merck Sharp & Dohme LLC | $65.60 | 2023 | Steglatro, Belsomra, Verquvo |
| Amgen INC. | $46.34 | 2023 | Repatha, Otezla |
| Radius Health, INC. | $40.42 | 2023 | Tymlos |
| Edwards Lifesciences Corporation | $38.13 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $34.91 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.24 | 2023-2024 | Xifaxan |
| Millicent US INC | $25.45 | 2025 | Intrarosa, Femlyv |
| Axsome Therapeutics, INC. | $24.26 | 2023 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.91 | 2023 | Injectafer |
| Organon LLC | $23.63 | 2025 | Nexplanon |
| Exact Sciences Corporation | $20.23 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.17 | 2024 | Ofev |
| Janssen Pharmaceuticals, INC | $20.10 | 2022 | |
| Sanofi Pasteur INC. | $18.59 | 2024 | |
| Idorsia Pharmaceuticals US INC | $15.84 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $6.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Rouser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.